surgery genitourinary complications
After post-cystectomy orthotopic bladder substitution, urinary leakage occurs in 0-70% of patients [6] , and in 5-30% prostatectomised men [7] . Nerve-sparing techniques have reduced these figures, depending on the selection of patients and the experience of the surgeon. At least 50% of prostatectomised men experience erectile dysfunction with some recovery during the first 18 months [7] . Dry ejaculation is recorded by 25-100% of cystectomised patients, and is also a consequence of retroperitoneal lymph node dissection (RPLND). Nerve-sparing RPLND has reduced this complication from almost 100% to <10% [8] .
digestive tract complication
Extensive resections of the small bowel may lead to diarrhoea, malabsorption and nutritional deficits. The care of colostomy today represents a minor problem, and colostomy should be considered in all cancer survivors with major fecal incontinence.
vascular, cardiac and pulmonary complications
After extensive pelvic or inguinal lymphadenectomy lymph edema in the leg(s) becomes a long-term problem in 6-20% of patients [9] . Lymph edema develops in up to 50% of breast cancer patients after axillary lymph node dissection with substantial risk reduction after the introduction of sentinel node biopsy only in metastases-free patients [10] . Early referral to a specialist physiotherapist is essential in the prevention of this morbidity.
endocrinological complications/fertility
After thyroid cancer surgery, life-long treatment with thyroxin is often required, sometimes with onset of substitution treatment after several years' delay and with the need to monitor the serum levels of calcium and magnesium regularly.
After unilateral orchiectomy, testicular dysgenesis in the remaining testicle is responsible for biochemical hypogonadism (low testosterone, elevated luteinising hormone (LH) in 17% of the testicular cancer survivors (TCSs) [11] .
Organ-preserving surgery is an option for women with lowrisk ovarian cancer and plans for future motherhood [12] .
secondary malignancy
After surgery alone, a subsequent cancer can develop due to a shared genetic susceptibility [13] [14] [15] or on the background of shared environmental or lifestyle factors.
After surgery for colorectal cancer, patients with identified familial or hereditary syndromes have an 80-100% risk of a new large bowel malignancy.
A contralateral breast cancer develops in 1-6% of breast cancer patients treated with surgery alone, with a 50-80% lifetime risk in patients with BRCA1 and BRCA2 mutations.
In 3-5% of testicular cancer patients, a contralateral testicular cancer may develop based on testicular dysgenesis.
other post-surgery complications Splenectomy in survivors after Hodgkin's lymphoma (HLSs) increases the risk of septicemia due to pneumococcus infection (2-4%). In Europe it is therefore recommended to vaccinate splenectomised HLSs every 5 years [16] .
Long-term survivors after limb amputation may experience stump prosthetic problems and stump phantom pain, whereas survivors after limb-sparing surgery are threatened by aseptic loosening and prosthetic fractures.
Little is known about autonomous dysfunction after major surgery often including resection of neural tissue. However, it has been shown that disturbed innervations of blood vessels in ª 2006 European Society for Medical Oncology the legs and disturbed perceptions of temperature are longterm complications after RPLND in TCSs [17] .
Neck dissection may affect the spinal accessory nerve and may lead to long-term scapular destabilisation with pain, weakness and deformity.
radiotherapy
Ionising radiation either leads to irreversible DNA changes followed by cell death, or DNA alterations, which are completely or partially reversible, in the latter case leaving a surviving, cell with mutations. The basis of radiotherapy is the recognition that cell death is achieved more often in malignant tumours than in normal tissues, high proliferation in a cell population generally favouring radio-sensitivity. Most radiotherapy-related longterm adverse radiation effects develop slowly with progression over several months and years. Long-term problems are related to cell death, followed by fibrosis, which is accelerated by ischaemic processes.
Though modern radiotherapy and modern imaging techniques assist the exclusion of non-malignant tumoursurrounding tissues from the target field, irradiation of organs and normal structures in a tumours' neighbourhood cannot always be completely avoided. Table 2 quantifies the radiosensitivity of different human tumours [18] .
urological complications
High-dose pelvic radiotherapy leads to moderate or severe functional disturbances of the urinary bladder in 6-8% of patients, clinically manifesting as dysuria, pollakisuria and hematuria [19] .
Radiation of a whole kidney by more than 15 Gy leads to clinically significant tubular and glomerular dysfunction, whereas doses ‡20 Gray (Gy) are tolerated if not more than one third of the kidney is irradiated [20] .
Hypertensive patients with prior abdominal radiotherapy should be evaluated for radiotherapy-induced stenosis of the renal artery.
digestive tract complications
Abdominal radiotherapy may be followed by chronic inflammation and fibrosis of the intestinal mucosa/submucosa, with thickening of the intima of the submucous small vessels and their gradual stenosis.
Gastrointestinal ulcera are observed in 2% of irradiated TCSs [21] .
Increased fecal urgency and fecal incontinence are frequent long-term sequels after pelvic radiotherapy [22] .
Retroperitoneal fibrosis may occasionally lead to stenosis of the ductus choledocus or ureters [23] .
After radiotherapy to the spleen at doses of more than 30 Gy the risk of infections is similar to that after splenectomy.
cardiac, vascular and pulmonary adverse effects
During mantle-field irradiation large parts of the pericardium and myocardium are irradiated together with the coronary arteries and the autonomous conduction system. Parts of the heart are also irradiated during adjuvant thoracic radiotherapy for breast cancer.
After total doses of >35 Gy, fibrosis develops due to endothelial cell dysfunction in the hearts' micro-circulatory system and the coronary arteries, resulting in cardiomyopathy, constrictive pericarditis, valvular disease and arrhythmia/ conduction disturbances [24] . Risk factors are the radiation dose per volume cardiac tissue, years since irradiation and young age at treatment. Late pulmonary radiation fibrosis is irreversible and in the first place must be avoided by adequate treatment techniques [25] .
The long-term effectiveness of new planning techniques in Hodgkin's lymphoma (HL) and breast cancer over recent yeats cannot be evaluated yet. However, doses as low as 2 Gy have been associated with increased 20-year risk of cardiac death in A-bomb survivors [26] .
endocrinological complications/fertility
After mantle-field radiotherapy 50% of HLSs develop primary thyroxin-requiring hypothyroidism [27] .
The direct gonadal adverse effects are highly dose-and agedependent. Persistent amenorrhea is the consequence of bilateral ovarian irradiation at doses of ‡20 Gy in the very young girl, and much lower doses may be followed by premature ovarian failure (POF) [28] in adults.
After testicular irradiation of >16 Gy, patients should be monitored for hypogonadism [29] . Testicular irradiation of >50 cGy is followed by transient arrest of spermatogenesis [30] , with 70% of TCSs being successful in their attempt to achieve post-treatment fatherhood [31] .
central nervous system
Depending on age and dose, radiation-induced injury to normal brain tissue presents as endocrine disturbances, cognitive sequels and damage to visual pathways, the middle and inner ear.
Severe neurotoxicity has been reported at 6% after 64.8 Gy compared to 2.5% after 50.4 Gy [32] . Magnetic resonance imaging (MRI) may show white matter changes, lacunar lesions, contrast enhancement and cerebral atrophy.
head and neck
Fibrosis and edema of the neck, problems with speech and swallowing, dryness in the mouth and teleangiectasis of the skin are common late side effects of radiotherapy to the head and neck region with important consequences on survivors' quality of life, dental status and sexuality.
secondary cancer
Radiotherapy increases the life-time risk of hematological and solid malignancies, the latter arising particularly often in the target field [33, 34] . TCSs surviving more than 10 years have a significantly increased relative risk (RR) of 2.7 to develop a secondary cancer within the target field as compared to RR 1.6 at other sites [33] . The RR of a second post-radiation malignancy is modified by host-related genetic and environmental factors. Thus, female HLSs with preserved ovarian function are at a significantly higher risk of developing breast cancer than those who have developed amenorrhea due to chemotherapy [35] . Cumulative 20-year risk of secondary brain tumour is 1.9% in adults irradiated for a pituitary tumour [36] . chemotherapy general Today most cancer patients receive combination chemotherapy, often with the addition of radiotherapy and surgery, and the individual drug's contribution to long-term toxicity is thus difficult to identify. Data on long-term chemotherapy-related toxicity in survivors after adult-onset cancer are scarce, particularly for newer drugs. A long-lasting belief that chemotherapy is less carcinogenic than radiotherapy can be disputed based on a recent study in TCSs, showing a significantly increased RR (1.8) for secondary solid cancer [33] .
alkylating agents
After treatment with high-doses of cyclophosphamide, renal toxicity (tubulopathy, glomerulopathy) may develop [37] .
Cyclophophamide is highly gonadotoxic and the risk of posttreatment infertility, hypogonadism and POF must always be considered, even after standard doses used in cancer therapy. Iphosphamide seems to be less gonadotoxic.
The risk of cyclophosphamide-associated secondary bladder cancer is well known [38] .
High-dose chemotherapy with cyclophosphamide or thiotepa implies a high risk of cognitive dysfunction [39] .
anthracyclines
The well-known risk of late-onset cardiotoxicity after anthracycline treatment (doxorubicin, epirubicin) of adult cancer has recently been reviewed [40] . Pathophysiologically, doxorubicin induces necrosis of the myocardium by dysfunctional mitochondria leading to insufficient function of the left ventricle, finally resulting in congestive heart failure. Cumulative doses of more than 300 mg/m 2 doxorubicin can safely be given, though subclinical cardiomyopathy has been reported in 20% of the patients treated with such doses [41] . Cumulative doses above 500 mg/m 2 should be avoided, with lower cut-off doses in patients with such risk factors as advanced age, mediastinal radiotherapy or cardiac co-morbidity. The cardiotoxic risk is apparently reduced by the use of epirubicin or liposomal conjugates.
Anthracyclines are only moderately gonadotoxic.
platinum compounds
Dose-dependent ototoxicity (tinnitus, hearing loss), peripheral neurotoxicity, Raynaud phenomenon and nephrotoxicity are the most frequent long-term adverse effects after cisplatin-based chemotherapy, observed in 20-25% of TCSs receiving standard cumulative doses of cisplatin (400 mg/m 2 ) [20, 42] . Hearing loss is predominantly detectable at frequencies >4000 Hz, thus often without large impairment of daily life communication.
Peripheral sensory neuropathy (parasthesias, dysesthesia) persists in 20% of the TCSs after standard treatment.
Sufficient hydration and avoidance of excessive serum concentrations during treatment probably reduce the risk of cisplatin long-term toxicity, in particular if cumulative doses >300 mg/m 2 are given [43] . Carboplatin is overall less toxic, but is, at least in testicular cancer, less effective [44] .
Cisplatin is only moderately gonadotoxic, and most TCSs regain spermatogenesis during the second or third posttreatment year [45] .
other drugs
The most important late toxicity after etoposide is the dosedependent development of a distinctive type of acute myeloid leukemia. In TCSs, cumulative doses of >2000 mg/m 2 result in leukemia in 2.6% of patients as compared to 0.5% if standard doses are applied [46] .
The risk of bleomycin-induced long-term lung toxicity is minimal [47] . Bleomycin may, however, at least in part, be responsible for Raynaud-like phenomenon in 20% of TCSs, and may also contribute to long-term cardiovascular morbidity in TCSs when administered together with cisplatin and etoposide [48, 49] .
After intrathecal chemotherapy with methotrexate there is a considerable risk of white matter necrosis with neurocognitive dysfunction, in particular if treatment includes cranial irradiation [50] . This risk is reduced, but not removed, if high doses of methotrexate are applied intravenously.
Sensory peripheral neuropathy is a long-term sequel after treatment with vinca alkaloids and probably also taxanes.
hormones
After long-term medical or surgical castration at least 50% of patients report hot flushes, and all experience sexual life impairment [51] . Other long-term effects are fatigue, muscle weakness, obesity and osteoporosis [51] [52] [53] , with transient symptomatic improvement during intermittent androgen ablation.
Monotherapy with oral anti-androgens as an alternative to castration reduces the risk of fatigue, decrease of sexual life and osteoporosis, but adds the risk of gynecomastia [52, 54] .
The post-menopausal symptoms due to estrogen deprivation are well known in breast cancer survivors using anti-estrogens (dry vagina, vaginal discharge, weight gain, thrombo-embolic events) [55] .
As tamoxifen has a weak estrogenic activity, the drug protects against osteoporosis. However, tamoxifen is regarded as a class I human carcinogen, and increases the risk of endometrial cancer [56] .
The long-term effects of aromatase inhibitors are known for anastrazole only [55] . This drug has almost no estrogenic effects, reduces the risk of thrombo-embolic events by 50% and is less carcinogenic, but is less protective against osteoporosis.
Many adult cancer patients receive moderate to high doses of corticosteroids during periods of their treatment, with the risk of altered glucose metabolism, osteopenia and avascular osteonecrosis [57] .
psychosocial effects and quality of life issues a statement from the USA [2] , the mean values of important quality of life dimensions in cancer patients without adverse side effects do not differ significantly from those of general population individuals without a prior malignancy. Admittedly, a subgroup of cancer survivors, probably those with multiple health complaints and/or mental distress, needs special assistance from the health care system. The patients' coping ability and his/her degree of response shifts [58] are essential mediators in the adaptive process during cancer survivorship.
conclusion
Cancer survivors display an increased risk of adverse effects, secondary cancer, cardiovascular morbidity and premature gonadal failure being the most severe ones. This risk can be reduced by appropriate pre-treatment tasks, which are based on the understanding of the pathophysiological processes. However, the risk cannot completely be abolished in the attempt to cure. Adequate pre-treatment information of the patient about his/her risk profile and early diagnosis and management of long-lasting adverse effects are essential cancer survivorship issues. In addition, cancer survivors can themselves lower their risk profile by ensuring a healthy lifestyle, which includes physical activity, healthy nutrition, no smoking and sensible alcohol habits. Ongoing and future research of long-term survivorship issues contributes to improved risk-adaptive treatment of future cancer patients.
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